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Abstract
Purpose: The cardiac and renal protective effects of phosphodiesterase-5 (PDE-5) inhibitors against ischemia-
reperfusion injury have recently been demonstrated in animal studies. We evaluated the effect of pretreatment
with the PDE-5 inhibitor zaprinast on warm renal ischemia in a rat model.
Methods: Female Sprague-Dawley rats underwent concomitant right nephrectomy and left renal hilar occlusion
for 30 minutes. Twelve animals were equally divided into three groups: Group 1 received no pharmacologic
pretreatment, group 2 was pretreated with zaprinast 10 mg/kg, and group 3 was pretreated with zaprinast
20 mg/kg. Zaprinast was dissolved in 25% dimethyl sulfoxide and given as a single intraperitoneal injection 30
minutes before surgery. Serum blood urea nitrogen (BUN) and creatinine levels, histopathology, and TUNEL
staining for apoptosis were assessed 24 hours postoperatively.
Results: The mean creatinine level for groups 1, 2, and 3 was 0.73 mg/dL, 0.55 mg/dL, and 0.38 mg/dL, re-
spectively. These values were not statistically different (P = 0.099). The mean BUN levels of 35.8 mg/dL for group 1,
27.3 mg/dL for group 2, and 23.3 mg/dL for group 3 were also statistically similar (P = 0.278). There were no
objective differences in histopathologic evaluation or TUNEL staining between the groups.
Conclusion: This study did not demonstrate a beneficial effect of zaprinast pretreatment on renal parameters
after warm ischemic injury.
Introduction
Partial nephrectomy has become a standard of care forthe treatment of patients with many small renal masses1
with similar oncologic outcomes to those of radical nephrec-
tomy.2 To help improve visualization and minimize blood
loss during this procedure, the renal vasculature is often oc-
cluded. Although kidney parenchyma is surgically spared,
the induced ischemia and subsequent reperfusion can lead to
functional nephron injury and loss.3
Several mechanisms are involved in the kidney dysfunc-
tion that follows a hypoxic insult.4 There is a vascular com-
ponent in which endothelial damage induces intrarenal
vasoconstriction, vascular smooth muscle dysfunction, and
vascular congestion. This further reduces renal blood flow
and potentiates tubular epithelial injury.5 A tubular compo-
nent develops as injured and dead epithelial cells are
sloughed into the tubules, obstructing urine flow, causing
transtubular backleak of filtrate and interstitial inflammation.6
The net effect is a decrease in glomerular filtration rate (GFR)
and cessation of urine production.5 On a molecular level, the
local hypoxia leads to a variety of secondary processes
causing cellular injury, including the intracellular accumu-
lation of calcium, the generation of reactive oxygen species,
depletion of adenosine triphosphate, and cellular apoptosis
or necrosis.7
Phosphodiesterases (PDEs) are a large group of struc-
turally related enzymes that catalyze the hydrolysis of 3,
5-cyclic mononucleotides to the corresponding inactive
nucleotide 5-monophosphate. There are 11 different families
of PDEs that differ in structure, tissue distribution, and af-
finity for substrates.8 The PDE-5 enzyme catalyzes the
breakdown of cyclic guanosine monophosphate (cGMP),
one of the primary potentiators of smooth muscle relaxa-
tion. It is particularly abundant in vascular smooth muscle9
and has also been identified in the kidney.10,11 In the penis,
nitric oxide released by parasympathetic neurons leads to
the production of cGMP and the resultant smooth muscle
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relaxation that causes erection. Because of their vasoactive
properties, PDE-5 inhibitors have received considerable at-
tention in recent years for their potential protective effect
against ischemia-reperfusion injury.9
The aim of this study was to evaluate the effect of zaprinast,
a PDE-5 inhibitor, on renal ischemic injury in a rat model.
Methods
Animals
Pathogen-free, adult female Sprague-Dawley rats (150–
200 g; Harlan Laboratories, Madison, WI) were housed in
temperature (23 – 3C) and light (12-hours light; 12-hours
dark cycle) controlled rooms with standard rodent chow and
water available ad libitum. All experiments were approved by
the Institutional Animal Care and Use Committee (IACUC) of
Loyola University Chicago. All procedures were conducted in
accordance with the Guide for Care and Use of Laboratory
Animals published by the National Institutes of Health, and
handling of animals was in accordance with institutional
guidelines and approved by the Loyola University IACUC.
Drug treatment and surgical methods
Animals were anesthetized with inhalational isoflurane
(Baxter, Deerfield, IL). They were placed on a warm heating pad
to maintain body temperature. Through a midline laparotomy
incision, right nephrectomy was performed. The left renal
hilum was then dissected, and a nontraumatic vascular clamp
was applied en bloc to the artery and vein. The clamp was left in
place for 30 minutes, during which time a warm saline-soaked
gauze pad was used to cover the abdominal incision. After
clamp removal, the abdomen was assessed for hemostasis, and
the incision was closed with 4-0 polyglactin suture.
Rats were divided into three groups. Group 1 (n = 4) un-
derwent surgery with no pharmacologic pretreatment.
Group 2 (n = 4) was treated with zaprinast 10 mg/kg, and
group 3 (n = 4) was treated with zaprinast 20 mg/kg.
Zaprinast (Tocris Bioscience, Bristol, United Kingdom) was
dissolved in 0.5 mL of 25% dimethyl sulfoxide and given as a
single intraperitoneal injection 30 minutes before the surgi-
cal procedure. Two animals underwent a sham procedure
during which a laparotomy incision was made and the ab-
domen was left open for 30 minutes with no nephrectomy or
renal ischemia.
Histopathology and laboratory analysis
Twenty-four hours postoperatively, all animals were
euthanized. Blood samples were drawn for determination
of serum blood urea nitrogen (BUN) and creatinine (Cr)
levels using the VetScan Classic automated machine
(Abaxis, Union City, CA). The animals were transcardially
perfused with saline followed by fixative. The left kidney
was removed, bisected along the nonhilar axis, and further
fixed in formalin. One half of the kidney was then em-
bedded in paraffin, sectioned, and stained with hematox-
ylin and eosin. The other half was frozen in liquid nitrogen
and stored at - 80C.
Histologic changes were examined by light microscopy.
Two different sections of each kidney were examined at 200X
power, and each section was divided into 10 different fields.
The histologic features of each field (20 fields per kidney) were
scored in a blinded fashion by a single renal pathologist (MP)
using the system outlined in Table 1.
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FIG. 1. The mean serum blood urea nitrogen (BUN) level of
animals in group 1 (no pretreatment), group 2 (pretreatment
with zaprinast 10 mg/kg), and group 3 (zaprinast 20 mg/
kg). Animals in the sham group underwent anesthesia for 30
minutes with no right nephrectomy or left hilar clamping.
FIG. 2. The mean serum creatinine (Cr) level of animals in
group 1 (no pretreatment), group 2 (pretreatment with
zaprinast 10 mg/kg), and group 3 (zaprinast 20 mg/kg).
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Assay
Terminal deoxynucleotidyl transferase dUTP nick end la-
beling (TUNEL) staining was performed using the ApopTag
Fluorescein In Situ Apoptosis Detection Kit (Chemicon In-
ternational) on tissue cryosections. The methodology was
performed in accordance with the manufacturer’s guidelines
with several minor alterations. Hoechst was used as a coun-
terstain. Positive staining was evaluated with fluorescence
microscopy, and samples were compared in a blinded fashion
by the senior investigator (FW).
Statistical analysis
Statistical analysis was performed using SPSS 16.0 for
Windows (SPSS, Chicago, IL). Mean serum BUN and Cr levels
and histologic scores were compared using the analysis of
variance (ANOVA) test. Statistical significance was consid-
ered at a P value of < 0.05.
Results
Laboratory data
The mean BUN level of animals in group 1 (no pretreat-
ment), group 2 (pretreatment with zaprinast 10 mg/kg), and
group 3 (pretreatment with zaprinast 20 mg/kg) was 35.8,
27.3, and 23.3 mg/dL, respectively (Fig. 1). An ANOVA test
comparing these values did not demonstrate a significant
difference between the groups (F2 = 1.48, P = 0.278). The mean
Cr level for Groups 1, 2, and 3 was 0.73, 0.55, and 0.38 mg/dL,
respectively (Fig. 2). Although the pretreated animals, espe-
cially at the higher dose, displayed a trend toward lower Cr
levels, the difference between the groups was not statistically
significant (F2 = 3.02, P = 0.099).
Histopathology
The mean histologic scores were 2.7 (group 1), 1.5 (group 2),
and 2.2 (group 3). These were not statistically different
(P = 0.174). Figure 3 demonstrates a box plot of the scores for
each group and highlights the variability of histologic find-
ings within groups, particularly group 1.
TUNEL assay
The number of TUNEL positive cells in the kidneys of
nontreated ischemia-reperfusion animals was similar to
those pretreated with zaprinast 10 mg/dL and zaprinast
FIG. 3. A box plot depicting the histologic scores in each
group. There was wide variability in the histology observed
among group 1 animals.
FIG. 4. Representative samples of
TUNEL staining from control and
groups 1–3. White arrows point to
TUNEL positive cells.
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20 mg/dL. A representative example from each group is
demonstrated in Figure 4.
Discussion
Several recent studies have examined the protective effect
of PDE-5 inhibitors on renal ischemia-reperfusion injury. In a
swine model, Lledo-Garcia and associates12 found that renal
vascular flow was higher and vascular resistance was lower in
animals treated with sildenafil citrate before renal auto-
transplantation with 45 minutes of warm ischemia. Choi and
colleagues13 used a rat model to evaluate the renoprotective
effects of sildenafil after ischemic injury. They found that sil-
denafil treated animals had more favorable functional and
histologic parameters than controls. Furthermore, they pro-
vided evidence that this protection may primarily be from the
inhibition of apoptosis and necrosis.13
Zaprinast, which was a lead compound for sildenafil, is an
inhibitor of cGMP-phosphodiesterases, particularly PDE-5
and PDE-6.14,15 Previously, zaprinast was shown to accelerate
the recovery from established acute renal failure in the rat
because of its ability to stimulate regional blood flow and raise
intracellular cGMP levels.16 We selected zaprinast for the
current study because of its wide commercial availability,
ease of use, and reliability in delivering a predefined dose. We
also hypothesized that its modest activity against other PDE
isoforms might enhance its renoprotective effect.
The medication was dosed based on previous work that
suggested that beneficial effects on regional blood flow and
cyclic mononucleotide levels without a significant reduction
in mean arterial pressure could be achieved at 10 to 20 mg/kg
doses.17–19 It is possible that the concentration of zaprinast
used in this study was too low to achieve a meaningful effect.
The 30-minute ischemic time for this experiment was based
on several of our own pilot studies. Using male Sprague-Dawley
rats weighing 250 to 350 g, Jablonski and coworkers20 concluded
that 60 minutes of warm renal ischemia with concomitant con-
tralateral nephrectomy was the most suitable model for testing
the efficacy of pretreatment regimens. When we used consid-
erably smaller females, however, this same insult was surviv-
able by only half of the animals, and complete coagulative
necrosis was observed histologically in the experimental kidney.
We then tested ischemia times of 15, 30, and 45 minutes and
found 30 minutes to be ideal based on functional and histologic
data.
Although statistical significance was not achieved, the
BUN and Cr levels of zaprinast-treated animals were lower
than those of control animals, particularly at the higher dose
of 20 mg/kg. The power to detect a difference was limited by
the small number of animals in each treatment group. We
suspect that these differences may have reached significance
with a larger sample size.
Our study did not find a difference in histology or in
TUNEL staining between kidneys of treated and untreated
animals. Interestingly, in his swine model of warm-ischemic
transplants, despite markedly improved vascular flow and
nitric oxide levels in the sildenafil group, Lledo-Garcia and
associates12 did not observe a histologic difference between
sildenafil- and placebo-treated animals. In contrast, in addi-
tion to significantly improved histologic parameters, Choi
and colleagues13 found that the number of TUNEL positive
cells was lower in sildenafil-treated animals. This led them to
conclude that the primary renoprotective effect was through
inhibition of apoptosis and necrosis.
There are several limitations of our study. The small
sample size in each group limited the statistical power. The
comparatively simpler anatomy of the rat kidney limits di-
rect translation to humans.5 We used serum BUN and Cr as
biomarkers of GFR, which have known limitations. Fur-
thermore, the bioavailability of zaprinast given by intra-
peritoneal injection and its duration of action could not be
directly assessed.
Conclusion
This study with a limited sample size did not demonstrate a
beneficial effect of zaprinast on renal ischemic injury. Al-
though there was a trend toward improvement of functional
and histologic parameters, significant differences were not
observed.
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ANOVA¼ analysis of variance
BUN¼ blood urea nitrogen
cGMP¼ cyclic guanosine monoposphate
Cr¼ creatinine
GFR¼ glomerular filtration rate




transferase dUTP nick end labeling
342 POLCARI ET AL.
